ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,120Medicare Part D Prescriptions Filled, Including Refills

Rank: 141 out of 761

$620K Total Retail Price of All Prescriptions

Rank: 65 out of 761

512 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

18% of this provider’s 512 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

15% of this provider’s 512 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

2% of this provider’s 6,410 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
LEVOTHYROXINE SODIUM 416 359 1 3
LISINOPRIL 353 251 2 1
HYDROCODONE-ACETAMINOPHEN 346 198 S3 3 5
ZOLPIDEM TARTRATE 260 144 4 22
SIMVASTATIN 226 159 5 2
GABAPENTIN 206 135 6 15
AMLODIPINE BESYLATE 192 160 7 6
OMEPRAZOLE 185 114 8 4
ATENOLOL 180 155 9 8
WARFARIN SODIUM 171 124 10 9
METFORMIN HCL 166 103 11 10
JANUVIA 148 123 12 113
CITALOPRAM HBR 148 90 12 19
OXYCODONE HCL 138 40 S2 14 24
POTASSIUM CHLORIDE 137 114 15 18
METOPROLOL SUCCINATE 131 109 16 16
ATORVASTATIN CALCIUM 131 119 16 12
FUROSEMIDE 129 103 18 7
METHADONE HCL 127 44 S2 19 75
TRAZODONE HCL 124 95 20 23
QUETIAPINE FUMARATE 119 61 21 90
ESTRADIOL 111 63 R 22 80
CYMBALTA 110 46 23 53
LAMOTRIGINE 105 39 24 174
LOSARTAN POTASSIUM 98 95 25 13
MORPHINE SULFATE ER 94 27 S2 26 38
TOPIRAMATE 81 36 27 186
PROAIR HFA 77 47 28 32
TRIAMTERENE-HCTZ 74 45 29 42
PREDNISONE 73 56 30 30
FLUOXETINE HCL 69 49 31 31
PANTOPRAZOLE SODIUM 69 62 31 40
OXYCODONE-ACETAMINOPHEN 66 52 S2 33 49
PRAVASTATIN SODIUM 62 53 34 20
TRAMADOL HCL 61 43 35 34
METOPROLOL TARTRATE 57 52 36 14
SYNTHROID 56 54 37 64
NEXIUM 54 47 38 98
DIOVAN 54 52 38 58
ALLOPURINOL 53 53 40 28
PREMARIN 52 26 R 41 88
DIGOXIN 52 37 41 43
ESCITALOPRAM OXALATE 51 51 43 102
CRESTOR 51 42 43 36
ADVAIR DISKUS 50 36 45 37
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 30, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.